1140 related articles for article (PubMed ID: 32675047)
1. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of
Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. Head-to-Head Comparison of
Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K
Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
8. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
Mazzone E; Gandaglia G; Robesti D; Rajwa P; Gomez Rivas J; Ibáñez L; Soeterik TFW; Bianchi L; Afferi L; Kesch C; Darr C; Guo H; Zhuang J; Zattoni F; Fendler WP; Amparore D; Huebner NA; Giesen A; Joniau S; Schiavina R; Brunocilla E; Mattei A; Dal Moro F; Moreno Sierra J; Porpiglia F; Picchio M; Chiti A; van den Bergh R; Shariat SF; Montorsi F; Briganti A
Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.
Dinnes J; Ferrante di Ruffano L; Takwoingi Y; Cheung ST; Nathan P; Matin RN; Chuchu N; Chan SA; Durack A; Bayliss SE; Gulati A; Patel L; Davenport C; Godfrey K; Subesinghe M; Traill Z; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012806. PubMed ID: 31260100
[TBL] [Abstract][Full Text] [Related]
11. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
12. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
Heetman JG; Lavalaye J; Polm PD; Soeterik TFW; Wever L; Paulino Pereira LJ; van der Hoeven EJRJ; van Melick HHE; van den Bergh RCN
Eur Urol Oncol; 2024 Apr; 7(2):204-210. PubMed ID: 37296065
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L
Eur Urol Oncol; 2024 Jun; 7(3):544-552. PubMed ID: 38061976
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI and
Privé BM; Israël B; Janssen MJR; van der Leest MMG; de Rooij M; van Ipenburg JA; Jonker M; Peters SMB; de Groot M; Zámecnik P; Hoepping A; Bomers JG; Gotthardt M; Sedelaar JPM; Barentsz JO; van Oort IM; Nagarajah J
Radiology; 2024 May; 311(2):e231879. PubMed ID: 38771185
[TBL] [Abstract][Full Text] [Related]
15. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
16. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
[TBL] [Abstract][Full Text] [Related]
17. Presurgical
Djaïleb L; Armstrong WR; Thompson D; Gafita A; Farolfi A; Rajagopal A; Grogan TR; Nguyen K; Benz MR; Hotta M; Barbato F; Ceci F; Schwarzenböck SM; Unterrainer M; Zacho HD; Juarez R; Cooperberg M; Carroll P; Washington S; Reiter RE; Eiber M; Herrmann K; Fendler WP; Czernin J; Hope TA; Calais J
Eur Urol; 2023 Dec; 84(6):588-596. PubMed ID: 37482512
[TBL] [Abstract][Full Text] [Related]
18. A comparison study of 68gallium-prostate-specific membrane antigen positron emission tomography-computed tomography and multiparametric magnetic resonance imaging for locoregional staging of prostate cancer.
Patel KS; Singh T; Raghuvanshi K; Sonar S; Chaudhari R
Urol Sci; 2024 Mar; 35(1):36-41. PubMed ID: 38566885
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of
Esen B; Seymen H; Tarim K; Koseoglu E; Bolukbasi Y; Falay O; Selçukbiricik F; Molinas Mandel N; Kordan Y; Demirkol MO; Tilki D; Esen T
Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
[TBL] [Abstract][Full Text] [Related]
20. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
Bodar YJL; Boevé LMS; van Leeuwen PJ; Baars PC; Nieuwenhuijzen JA; van Haarst EP; Oddens JR; Donswijk ML; van Riel LAMJG; Scheltema MJ; Meijer D; Hendrikse NH; Oprea-Lager DE; Vis AN
BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]